Loading
JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
JSKN003 is an investigational agent whose form is not stated in the registry developed by Jiangsu Alphamab Biopharmaceuticals and Shanghai JMT-Bio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JSKN003 should be administered intravenously on the first day of each 3-week cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06079983 (JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects) and NCT06846437 (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05744427, plans to enrol 725 participants with primary completion was scheduled for 2026-07-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.JSKN003's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JSKN003" OR ABSTRACT:"JSKN003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JSKN003, not a curated reading list.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Alphamab Oncology, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Alphamab Oncology and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.